Lysosomal Enzyme Market Report 2026

The lysosomal enzyme market size has grown strongly in recent years. It will grow from $10.07 billion in 2025 to $10.7 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to lysosomal storage disease awareness, orphan drug programs, hospital-based genetic treatment, recombinant enzyme development, rare disease research funding.

The lysosomal enzyme market size is expected to see strong growth in the next few years. It will grow to $13.49 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to gene therapy integration, newborn screening expansion, personalized enzyme therapies, biopharmaceutical manufacturing scale-up, global rare disease initiatives. Major trends in the forecast period include expansion of enzyme replacement therapies, growing focus on rare genetic disorders, increased investment in recombinant enzymes, advances in gene and enzyme therapy, rising diagnostic rates for lysosomal diseases.

The increasing adoption of gene therapy is expected to drive the growth of the lysosomal enzymes market in the coming years. Gene therapy involves altering or replacing genes within a person’s cells to treat or prevent disease. Its adoption is rising due to advances in delivery vectors and demonstrated long-term efficacy, making gene therapy a viable and potentially curative option for genetic disorders. Lysosomal enzyme therapies often serve as initial or complementary treatments to manage symptoms and stabilize patients while gene therapy takes effect, sustaining the demand for these products. For instance, in April 2024, according to the American Society of Gene & Cell Therapy, a US-based non-profit organization, the number of phase III gene therapy clinical trials increased by 10% in 2023, marking the first quarterly growth since 2022. Therefore, the increasing adoption of gene therapy is expected to boost the lysosomal enzymes market.

Major companies in the lysosomal enzymes market are focusing on strategic partnerships to expand diagnostic capabilities and accelerate the development of novel therapies. Strategic partnerships are collaborative agreements that combine resources or expertise to achieve mutual goals and strengthen competitive advantage. For example, in February 2024, a Spain-based biotechnology company partnered with Biosidus, an Argentina-based biotechnology company, to manufacture the active enzyme ingredient Agalsidase Beta. This collaboration represents a significant advancement in the development and production of treatments for rare diseases, particularly Fabry disease, which arises from lysosomal enzyme deficiency, and underscores a commitment to accessible biopharmaceutical innovation.

In March 2024, CENTOGENE, a Germany-based biotechnology research company, partnered with Takeda Pharmaceutical Company Limited to enhance global access to rapid and reliable diagnostics for rare lysosomal diseases. This partnership aims to improve early detection and treatment outcomes, particularly in underserved communities. Takeda Pharmaceutical Company Limited, based in Japan, is a leading provider of lysosomal enzymes.

Major companies operating in the lysosomal enzyme market are Sanofi SA, BioMarin Pharmaceutical Inc., Amicus Therapeutics Inc., JCR Pharmaceuticals Co. Ltd., Protalix BioTherapeutics Inc., Takeda Rare Diseases (Shire), Ultragenyx Pharmaceutical Inc., Orchard Therapeutics plc, Sangamo Therapeutics Inc., Avrobio Inc., Greenovation Biotech GmbH, Chiesi Global Rare Diseases, GC Pharma, Pfizer Rare Disease (through Spark & partnered LSD programs), Idorsia Pharmaceuticals Ltd., Abeona Therapeutics Inc., Selecta Biosciences Inc., Denali Therapeutics Inc., Passage Bio Inc., Freeline Therapeutics plc, REGENXBIO Inc., Homology Medicines Inc., LogicBio Therapeutics Inc., Allievex Corporation, Reneo Pharmaceuticals Inc., Lysogene SAS, Sio Gene Therapies Inc., Anika Therapeutics Inc., ArmaGen Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., Merck KGaA (MilliporeSigma), Agilent Technologies Inc.,

North America was the largest region in the lysosomal enzymes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lysosomal enzyme market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lysosomal enzyme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created significant cost pressure in the lysosomal enzyme market by increasing prices for recombinant enzymes, bioreactor inputs, purification reagents, and cold-chain logistics. Enzyme replacement therapies for Gaucher, Pompe, and Niemann-Pick diseases are most affected, particularly in North America and Europe due to dependence on imported biologics. Hospitals and pharmaceutical companies face higher treatment and R&D costs. Positively, tariffs are accelerating regional biomanufacturing and enzyme production facilities.

The lysosomal enzyme market research report is one of a series of new reports that provides lysosomal enzyme market statistics, including lysosomal enzyme industry global market size, regional shares, competitors with a lysosomal enzyme market share, detailed lysosomal enzyme market segments, market trends and opportunities, and any further data you may need to thrive in the lysosomal enzyme industry. This lysosomal enzyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lysosomal enzymes are specialized hydrolytic enzymes located within lysosomes, the membrane-bound organelles of eukaryotic cells. They play a vital role in cellular digestion by breaking down biological macromolecules such as proteins, lipids, carbohydrates, and nucleic acids. Deficiencies or dysfunctions in these enzymes can result in severe genetic disorders called lysosomal storage diseases, where undigested materials accumulate in cells and disrupt normal cellular functions.

The main types of lysosomal enzymes include acid alpha-glucosidase, acid sphingomyelinase, beta-glucocerebrosidase, and hexosaminidase. Acid alpha-glucosidase helps break down glycogen into glucose within lysosomes. These enzymes are used to treat conditions such as Gaucher disease, mucopolysaccharidosis, Pompe disease, and others. They are sourced from recombinant, natural, or synthetic origins and are applied in enzyme replacement therapy, research and development, diagnostics, and gene therapy. Lysosomal enzymes are utilized in hospitals, diagnostic laboratories, research institutions, and pharmaceutical companies.

The lysosomal enzymes market consists of sales of small molecule drugs, diagnostic kits, nutritional supplements, infusion kits, and accessories. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.